AU
CA
NZ
UK
US
IND
Kalkine has a fully transformed New Avatar.
ResApp Health Limited
RAP Details
ResApp Health Limited (ASX: RAP) is developing healthcare solutions to help doctors and enable patients to diagnose and operate respiratory disease on smartphones without additional hardware. ResApp’s core technology diagnoses respiratory diseases like pneumonia, bronchiolitis, bronchitis, chronic obstructive pulmonary disease, and asthma.
Results Performance (Half-Year Ended 31 December 2020 – H1FY21)
Key Data (Source: Company Reports)
Fourth Quarter Activities Report (Q4FY21) – Released on 30 July 2021
Key Risks:
The company is exposed to credit risk, liquidity risk, and interest rate risk. The company is exposed to the risk of the company’s product not being widely accepted as anticipated by the company. Also, it is exposed to significant technical change, adapted by the competitor.
Outlook:
As per the management, the company is focused on progressing the commercial pipeline, closing deals with Ilara Health (Kenya) and Doctors on Demand (Australia), the extension of the Medgate pilot, and strategies multiple lucrative commercial discussions. These deals not only grow the direct use of the technology by clinicians and patients but also establish themselves to telehealth providers, healthcare systems, clinicians, and patients globally. The company is also investing in its product development, with clinical research in COVID-19 and COPD.
Technical Analysis
Weekly Chart
Source: REFINITIV, Note: The purple color line in the chart shows RSI (14-period) and the yellow color line represents trend line.
On the daily chart, RAP stock prices are continuously sustaining above the downward sloping trend line and taking the support of the same. Furthermore, the momentum indicator RSI (14-period) is trading near an oversold zone (~35.18 levels), indicating a possibility of the upside rebound from the current level. A crucial support level for the stock, is placed at AUD 0.033, while the key resistance level is placed at AUD 0.052.
Stock Recommendation:
The stock fell by ~25.9% in 3 months and ~71.4% in 1 year. It has made a 52-week low and high of $0.040 and $0.155, respectively.
Driven by the optimism by the management, current trading levels, and positive long-term outlook, we recommend a ‘Speculative Buy’ rating on the stock at the current market price of $0.040 per share, down 2.440% on 30th July 2021.
Kyckr Limited
KYK Details
Kyckr Limited (ASX: KYK) offers real-time access to legally authoritative global company data through a single platform by connecting users to over 180 company registries and 170+ million legal entities in 120 countries.
Results Performance (Half-Year Ended 31 December 2020 – H1FY21)
Key Data (Source: Company Reports)
Fourth Quarter Activity Report Ended 30 June 2021 – Released on 29 July 2021
Key Risks:
The company’s intellectual property rights are not protected by any registered body in any jurisdiction. Also, the existing management team is the key people for growth plans. The finances of the company depend on the movement in exchange rates between the Australian Dollar and several other foreign currencies.
Outlook:
As per the management, the company is cementing its position in the competitive market with positive outlook for Q1FY22, primarily driven by increase in onboarding volumes. Moreover, the company has strong partnership leads with 35 opportunities under active management and launch of UBO Verify service, a new variant, to become a new source of revenue generation in FY22. Also, new SaaS Enterprise Portal is expected to be launched in Q2FY22. Importantly, easing of COVID-19 restrictions are signaling promising opportunities ahead.
Technical Analysis
Weekly Chart
Source: REFINITIV, Note: The purple color line in the chart shows RSI (14-period) and the yellow color line represents trend line.
On the daily chart, KYK stock prices are hovering near its horizontal trend line support zone at AU$0.0369 and prices are sustaining above the trend line. Moreover, the momentum oscillator RSI (14) is trading at ~37.45 level and formed a positive divergence indicating a possibility of the upside recovery from the current level. A crucial support level for the stock, is placed at AU$0.036, while the key resistance level is placed at AU$0.052.
Stock Recommendation:
The stock rose by ~23.2% in 3 months and ~48.8% in 1 year. It has made a 52-week low and high of $0.040 and $0.096, respectively.
Driven by the strong management, current trading levels, and significant rise in volume, and new order wins, we recommend a ‘Speculative Buy’ rating on the stock at the current market price of $0.043 per share, down 4.445% on 30th July 2021.
Note 1: The reference data in this report has been partly sourced from REFINITIV.
Note 2: Investment decisions should be made depending on the investors’ appetite on upside potential, risks, holding duration, and any previous holdings. Investors can consider exiting from the stock if the Target Price mentioned as per the analysis has been achieved and subject to the factors discussed above alongside support levels provided.
Technical Indicators Defined:-
Support: A level where-in the stock prices tend to find support if they are falling, and downtrend may take a pause backed by demand or buying interest.
Resistance: A level where-in the stock prices tend to find resistance when they are rising, and uptrend may take a pause due to profit booking or selling interest.
Stop-loss: It is a level to protect further losses in case of unfavorable movement in the stock prices.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine do not hold interests in any of the securities or other financial products covered on the Kalkine website.
Please wait processing your request...